Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Devin Mistry

Otolaryngology Wyoming, MI Doctor of Osteopathy

NPI 1508129123 CMS profile 250038

1555 44Th St Sw, Wyoming, MI 49509

Open in the dashboard

General payments

$23,054

118 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Devin Mistry of Wyoming, MI is reported in the CMS Open Payments database as having received $23,054 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,825 32
2024 General $1,043 11
2023 General $1,472 18
2022 General $638 9
2021 General $1,195 16
2020 General $709 8
2019 General $1,172 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Devin Mistry
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Devin Mistry were reported at $16,825. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Devin Mistry Otolaryngology median Middle half National median
2019 $1,172 $194 $82–$512 $163
2020 $709 $118 $42–$280 $114
2021 $1,195 $167 $63–$444 $132
2022 $638 $216 $84–$545 $149
2023 $1,472 $235 $93–$588 $160
2024 $1,043 $280 $111–$699 $164
2025 $16,825 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $17,430 41 payments
  2. Medtronic, Inc. $2,325 23 payments
  3. Intersect ENT, Inc. $1,742 16 payments
  4. Acclarent, Inc $714 13 payments
  5. Integra LifeSciences Corporation $271 4 payments
  6. Medtronic USA, Inc. $195 3 payments
  7. Preceptis Medical, Inc. $149 2 payments
  8. Aerin Medical Inc. $49 4 payments
  9. ALK-Abello, Inc $48 3 payments
  10. Olympus America Inc. $33 2 payments
  11. Other $99 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,600 6 payments
  2. Food and Beverage $8,099 107 payments
  3. Travel and Lodging $355 5 payments
Products named General payments · program years 2019–2025
  1. SCOPIS ENT $11,926 18 payments
  2. MINIFESS BLAKESLEY FORCEPS 45 $1,874 2 payments
  3. LATERA $1,800 1 payment
  4. PROPEL Otolaryngology (Ear, Nose, Throat) $1,470 14 payments
  5. NIM Vital $932 8 payments
  6. PROPEL Otolaryngology (Ear, Nose, Throat) $647 7 payments
  7. TruDi NAV Cable $378 4 payments
  8. MEDLINE INDUSTRIES, INC. $336 2 payments
  9. STEALTHSTATION S8 PLATFORM $283 2 payments
  10. INSPIRA AIR $271 4 payments
  11. Other $4,398 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

662

Median for Otolaryngology: 297

Drug cost

$14,004

Median for Otolaryngology: $6,314

Branded share of claims

17.5%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 74 $2,798
Cevimeline Hcl Generic 11 $2,412
Azelastine Hcl Generic 99 $2,051
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 14 $2,044
Fluticasone Propionate Generic 96 $1,378
Clonazepam Generic 11 $686
Budesonide Generic 11 $588
Doxycycline Hyclate Generic 64 $465
Mupirocin Generic 69 $344
Carbamazepine Generic 12 $286

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$77,720

Medicare's payments for the services billed

Medicare patients

167

Average age 72

Services billed

582

92 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 49%
Ischemic heart disease 26%
Depression 25%
Diabetes 23%
COPD 21%
Atrial fibrillation 19%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record